Clinical Trial Update: In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluated autologous invariant natural killer (iNKT) cells expanded in vitro for cancer therapy in malignant melanoma and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Autologous invariant natural killer cells (Invariant natural killer cells (iNKT))

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: Malignant Melanoma | Phase 1 | Status: COMPLETED